Nearly two-thirds of patients with colorectal cancer indicate financial burdens
the ONA take:
According to a new study published in the journal Medical Care, researchers at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, have found that about 62% of patients with colorectal cancer report some form of financial burden as a result of their cancer treatment.
For the study, the researchers surveyed 956 patients who had been treated for stage 3 colorectal cancer. Based on seven questions about financial burden, 29% indicated one to two areas of burden, 23% indicated three to four areas of burden, and 9% indicated 5 or more burdens. The questions referred to whether the patients had used savings, borrowed money, missed bill payments, or cut back spending on items like food, clothing, or activities.
The researchers found that the financial burden was highest among patients who received chemotherapy. In addition, younger, working patients with low-incomes were more likely to experience financial burdens as they could not afford to take time off from their jobs.
Their findings suggest that policy changes should be urged to allow support for patients who need time off from work to receive cancer care. The researchers recommend that patients speak with their physicians about their financial concerns.
About 62% of patients with colorectal cancer report some form of financial burden.
Nearly two-thirds of patients treated for colorectal cancer reported some measure of financial burden due to their treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The burden was greatest among patients who received chemotherapy and among younger patients who worked in low-paying jobs.
The study surveyed 956 patients who had been treated for stage 3 colorectal cancer. Among this group, chemotherapy is known to increase survival by up to 20 percent and is routinely recommended following surgery.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|